Meet Ivan

63-year-old carpenter who is anticipating his daughter’s graduation from college as she is the first in the family.

I got sick pretty fast from my kidney cancer. They say it’s not good, but my daughter is graduating from college in a few months—seeing her get her degree—it’s all I want.”

MEDICAL HISTORY: Has anemia and presented with blood in his urine

INITIAL DIAGNOSIS: Advanced renal cell carcinoma (RCC) with a clear cell histology and neoplastic metastatic disease; scheduled for radiotherapy


  • RCC is metastatic and Ivan is treatment naïve
  • ECOG performance status: 1
  • MSKCC risk: intermediate
  • Karnofsky performance status (KPS): 70%

In COMPARZ, VOTRIENT demonstrated efficacy across a wide range of patients1,2:

85% of patients had a favorable or intermediate MSKCC risk

75% of patients had a 90 or 100 KPS
Patient age ranged from 18 to 88 years

When choosing first-line treatment, what therapy do you consider?

Hypothetical patient case study.

References: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.